Vibecotamab is under clinical development by Xencor and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Vibecotamab’s likelihood of approval (LoA) and phase transition for Chronic Myelomonocytic Leukemia (CMML) took place on 09 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
In addition, the same event on 09 Aug 2022 decreased Vibecotamab’s LoA and PTSR for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), decreased PTSR for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), decreased PTSR for Myelodysplastic Syndrome, and decreased PTSR for Refractory Acute Myeloid Leukemia.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vibecotamab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Vibecotamab(XmAb-14045) is under development for the treatment of hematologic malignancies such as relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, myelodysplastic syndrome and chronic myeloid leukemia. It is administered intravenously. It is an extended bi-specific monoclonal antibody which contains both tumor antigen binding domain CD123 and cytotoxic T-cell binding domain (CD3 binding domain). The drug candidate is developed based on XmAb antibody engineering technology (bi-specific technology).
Xencor is a clinical stage biopharmaceutical company that focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Its Plamotamab is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. . Xencor is headquartered in Monrovia, California, the US.
Quick View Vibecotamab LOA Data
|Highest Development Stage|